Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 16/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.40 |
| ▸ | GABRD | O14764 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.40 |
| ▸ | GABRE | P78334 | 2/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005133 | 0.81 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2141766 | 0.79 | SCN9A (0.43) | SCN9ACYP2C9SCN5ACYP3A4CYP2D6 | |
| SCHEMBL1997629 | 0.74 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3825780 | 0.73 | GABRA2 (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6709936 | 0.70 | GABRB3 (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7645994 | 0.69 | GABRB3 (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7713193 | 0.67 | GABRB3 (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22093638 | 0.67 | CES2 (0.45) | KMT2A | |
| SCHEMBL11700031 | 0.66 | SCN9A (0.55) | SCN9AKMT2AL3MBTL1 | |
| SCHEMBL2835184 | 0.66 | GABRA2 (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084486-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-7960426-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | ZOETIS SERVICES LLC | 2009-05-28 | — | — | US | disclosed |
| US-7514464-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| EP-1705989-B8 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| EP-1705989-B1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7435753-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2008-10-14 | — | — | US | disclosed |
| EP-1705989-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | Pfizer Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| US-20060014802-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2006-01-19 | — | — | US | disclosed |
| US-20050148649-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2005-07-07 | — | — | US | disclosed |
| WO-2005060749-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | SCN9A 603/4885GABRP 1847/4885GABRD 2228/4885 |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | SCN9A 603/4885GABRP 1847/4885GABRD 2228/4885 |
| US-20050148649-A1 | Substituted arylpyrazoles | CYP3A4, CYP4B1, CYP1B1 | SCN9A 4168/4885GABRP 982/4885GABRD 1657/4885 |
| US-20060014802-A1 | Substituted arylpyrazoles | CYP4X1, ARG1, CYP2C9 | SCN9A 806/4885GABRP 2045/4885GABRD 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.